Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

Cost and committee reports

Official records Congress.gov attaches to H.R. 6227.

• Constitutional authority statementThe sponsor’s statement of where the Constitution gives Congress the power to pass this bill. Statement by Mr. SCHWEIKERT, as printed in the Congressional Record (Vol. 169, No. 182, November 3, 2023, Page H5405):
  Article 1 Section 8 of the U.S. Constitution The single subject of this legislation is: To amend the Federal Food, Drug, and Cosmetic Act to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.
  Source: Congress.gov, Congressional Record November 3, 2023 ↗

  Evidence

  Field in the Congress.gov record

  constitutionalAuthorityStatementText

  Statement length

  269 characters

  Congress.gov bill record

  H.R. 6227, 118th Congress

  Congress.gov API record

  https://api.congress.gov/v3/bill/118/hr/6227

  Record last updated by Congress.gov

  July 23, 2024

  PORKER copy retrieved

  September 14, 2026

  Stored copy, SHA-256 of the file

  bd5261fe2f10eb68ebbd0bfeb2e8e59f1bf41b22b661138637496b048712dcae

  PORKER shows the statement exactly as printed, with the page markup removed. It is the sponsor’s claim; it is not a legal finding.

Congress.gov’s record for this bill does not list a CBO cost estimate or a committee report (as of July 23, 2024). Not every bill gets one.

From the Congress.gov bill record for H.R. 6227, last updated July 23, 2024. PORKER’s copy was retrieved September 14, 2026 and is refreshed nightly. Open “Evidence” on any line for the record, field and file fingerprint.